Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

Multiple Sclerosis Journal

Volumn 19, Issue 9, 2013, Pages 1236-1237

  Laroni, A ^a   Brogi, D ^a   Milesi, V ^a   Abate, L ^a   Uccelli, A ^a   Mancardi, G L ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FINGOLIMOD; GLATIRAMER; METHYLPREDNISOLONE; NATALIZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; ITALY; LETTER; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; OPEN STUDY; RECURRENCE RISK; RISK REDUCTION; SKIN MANIFESTATION; TIME TO TREATMENT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84881034670     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512468498     Document Type: Letter

References (6)

1. Daelman L, Maitrot A, Maarouf A, et al. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler. 2012 ; 18 (11). 1647-1649
2. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 ; 366: 1870-1880
3. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009 ; 72: 402-409
4. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 ; 76: 1858-1865
5. Rispens T, Vennegoor A, Wolbink GJ, et al. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler. 2012 ; 18: 899-901
6. Ifergan I, Kebir H, Alvarez JI, et al. Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on alpha4 integrin. Brain. 2011 ; 134: 3560-3577